Thalidomide Improve Outcomes as Maintenance Therapy in Peripheral T- Celll Lymphoma

Peripheral T-cell lymphoma (not -specified) is an rare presentation of non-Hodgking Lymphoma, associated with a an worse prognostic. Multiple schedules, including the introduction of new drugs, and until no clear benefit has been observed, and in some, severe toxicities limited the use of these regimens. We performed an gemcitabine based chemotherapy, with two drugs that’s is considered in the treatment of T-cell lymphomas, etoposide and methotrexate, and introducing the use of maintenance with thalidomide. Progression-free survival (PFS) was better in patients that received thalidomide:69.9% (95% Confidence interval (CI): 67.2% to 75.4) compared with control group: 48.8% (43.2 % to 54.5 %), (p < 0.001): also overall survival (OS): 72.0% (95% CI: 67.7% to 76.9%) compared with control group: 51 % to 69.0%) (p < 0.001) Moreover, the PFS and OS were better that most of the published reports, We show that the control group un scheme based in pharmacological drugs, could be better that more toxic a] schedules. More studies are necessary to confirm our results.